EANS-News: Agennix AG Reports Financial Results for First Quarter of 2011
Quarter highlighted by completion of enrollment in talactoferrin Phase III FORTIS-M trial and issuance of key U.S. patent for talactoferrin in oncology Further inquiry note: Agennix AG Barbara Mueller Manager, Investor Relations & Corporate Communications Tel.: +49 89 8565-2693 ir@agennix.com In the USA: Laurie Doyle Senior Director, Investor Relations & Corporate ...